An Adaptive-design Prospective Cohort Study of Watch and Wait Strategy in Patients With Locally Advanced Rectal Cancer

Fudan University

Status and phase: Not yet enrolling; Phase 2

Conditions: Rectal Cancer

Treatments: Drug: Capecitabine (Xeloda) Pharmacogenetic Test Reagents; Radiation: IMRT; Drug: 5Fluorouracil; Drug: irinotecan; Drug: Oxaliplatin; Drug: Tislelizumab

Study type: Interventional

Funder types: Other

Identifiers

NCT04443543

CARTOnG-2001

Details and patient eligibility

About

The study is designed to test the hypothesis that the clinical complete response (CCR) rate of patients with locally advanced rectal cancer (LARC) treated with neoadjuvant chemoradiotherapy will increase after an adaptive-design paradigm, as well as the rate of 2-year organ preservation, recurrence, quality of life, DFS and OS.

Full description

1. Primary objective:

   Evaluate the CCR rate of low rectal cancer using adaptive and optimized chemotherapy and radiotherapy strategies (all population and dMMR/MSI-H subgroup)

2. Secondary objectives:

   2.1 Evaluate the 2-year anal preservation rate, recurrence rate, quality of life, DFS and OS 2.2 Explore the subgroup of patients suitable for observation.

3. Outline:

Patients after long-course chemoradiation are grouped based on their MSI-H/dMMR status. For patients with MSI-H/dMMR, consolidation immunotherapy of Tislelizumab (BGB-A317) will be assigned. For patients with MSS/pMMR, consolidation chemotherapy will be given according to their tumor response. After completion of consolidation therapy, those who reach clinical complete response will receive organ preservation (watch and wait) strategy in place of radical surgery. During treatment, once local regrowth occurs or poor tumor response, total mesorectal excision (TME) surgery will be performed.

Enrollment: 222 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• pathological confirmed adenocarcinoma
• clinical stage T2-4 and/or N+, inappropriate for local excision
• the distance from anal verge less than 5 cm, or considered inappropriate for anal preservation by surgeons.
• Strong desire to preserve the anus, able to receive close surveillance for at least 2 years after chemoradiotherapy.
• without distance metastases
• aged between 18 to 75 years old.
• performance status score: 0~1
• UGT1A1*28 6/6 or 6/7
• sign the inform consent

Exclusion criteria

• pregnancy or breast-feeding women
• serious medical illness
• difficult to achieve complete response assessed by current evidence: the maximal diameter of tumor >10cm; the maximal diameter of lateral lymph node >2cm; baseline CEA>=100; biopsy pathology confirmed signet ring cell carcinoma components; digital rectal examination found that the tumor is peri-narrowed.
• baseline blood and biochemical indicators do not meet the following criteria: neutrophils≥1.5×10^9/L, Hb≥90g/L, PLT≥100×10^9/L, ALT/AST ≤2.5 ULN, Cr≤ 1 ULN
• DPD deficiency
• UGT1A1*28 7/7

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

222 participants in 2 patient groups

Arm 1

Experimental group

Description:

Arm 1 includes patients with MSS/pMMR. In this arm, patients receive consolidation chemotherapy after neoadjuvant chemoradiation (nCRT). The chemotherapy regimens either XELIRI or FOLFIRINOX, and the cycles of chemotherapy depend on patient tumor responses. For patients who reach cCR will enter the "W\&W" cohort and omit radical surgery, while those without cCR will receive radical surgery.

Treatment:

Radiation: IMRT

Drug: Capecitabine (Xeloda) Pharmacogenetic Test Reagents

Drug: irinotecan

Drug: Oxaliplatin

Drug: 5Fluorouracil

Arm 2

Experimental group

Description:

Arm 2 includes patients with MSI-H/dMMR status. In this arm, patients receive consolidation immunotherapy of 3 cycles of tislelizumab after nCRT. For patients who reach cCR will enter the "W\&W" cohort and omit radical surgery, while those without cCR will receive radical surgery.

Treatment:

Drug: Tislelizumab

Radiation: IMRT

Drug: Capecitabine (Xeloda) Pharmacogenetic Test Reagents

Drug: irinotecan